LeukoStrat CDx FLT3 Mutation Assay: New entry in the field of companion tests
April 30, 2017 – The American Food and Drug Administration (FDA) just approved Midostaurin (Rydapt) for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) who carry particular genetic mutations in the FLT3 (CD135) gene, in combination …
LeukoStrat CDx FLT3 Mutation Assay: New entry in the field of companion tests Read more »